A Phase 3 interventional study of Lebrikizumab and Montelukast in Asthma, sponsored by Hoffmann-La Roche. Completed at 82 sites in 11 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-17.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing lebrikizumab in Asthma — none open to participants now, none under way, none of them phase 3. lebrikizumab · Asthma.
Among the 12 studies testing lebrikizumab in Asthma, this one is the 4th largest by enrollment, is one of 3 that started in 2014, is one of 5 in phase 3, and was the 10th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →None of the 12 studies testing lebrikizumab in Asthma is open now. The open studies under Asthma, anywhere →
lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2014.
This study's enrollment of 313 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 224 across the 12 interventional studies. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 2 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
41 studies in Asthma by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 39 finished, 16 (41%) have results posted.
Among the 41 studies in Asthma by Hoffmann-La Roche, this one is the 11th largest by enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2014, is one of 9 in phase 3, and was the 33rd registered.
Hoffmann-La Roche’s Asthma studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing lebrikizumab in Asthma, from their registry updates:
Among Hoffmann-La Roche’s 41 in Asthma:
This tab as a report to print or save as PDF → With an account.
This Phase III, randomized, double-blind, placebo-controlled, multicenter study will assess the efficacy and safety of lebrikizumab in adult patients with mild to moderate asthma treated with short-acting beta-agonist (SABA) therapy alone. Patients will be randomized in a 1:1:1 ratio to receive either blinded lebrikizumab or placebo treatment by subcutaneous (SC) injection (every 4 weeks for a total of 3 doses) or open-label treatment with Singulair (Montelukast; 10 mg daily). Time on study treatment will last 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Lebrikizumab
Other: Placebo
Drug: Montelukast
Lebrikizumab 125 mg subcutaneous (SC) injection given on Days 1, 29, and 57
Also known as: RO5490255
10 mg tablet given orally once daily for 12 weeks, according to the approved label.
Also known as: Singulair
Lebrikizumab-matched placebo SC injection given on Days 1, 29, and 57
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12
FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. The active comparator treatment arm of open-label montelukast was included in the study design so that the sensitivity of the study could be evaluated with respect to the primary outcome measure, FEV1. Two mixed-effect models of repeated measures (MMRM) were used to estimate the absolute change from baseline values: one for the lebrikizumab vs. placebo primary comparison and the second for the montelukast vs. placebo sensitivity comparison.
Time frame: Baseline through Week 12
Lebrikizumab vs. Placebo: Change From Baseline in Asthma Reliever Medication Use at Week 12
Participants could only receive SABA therapy for asthma treatment as asthma reliever medication (\<10 puffs daily). SABA use was recorded in the eDiary. A mixed-effect model of repeated measures (MMRM) was used to estimate the absolute change from baseline values for the comparison between the double-blind lebrikizumab and placebo study arms.
Time frame: Baseline through Week 12
Lebrikizumab vs. Placebo: Change From Baseline in the Standardized Asthma Quality of Life Questionnaire (AQLQ[S]) Overall Score at Week 12
The AQLQ\[S\] was used to assess the participant's asthma-specific health-related quality of life. The 32-item questionnaire contains four domains: activity limitations, symptoms, emotional function, and environmental stimuli. The AQLQ\[S\] has a recall specification of 2 weeks. Participants were asked to think about how they had been during the previous 2 weeks and to respond to each of the 32 questions on a 7-point scale (7 = not impaired at all; 1 = severely impaired). An increase in the AQLQ score indicates a better quality of life. The overall AQLQ score is the mean of all 32 responses and the individual domain scores are the means of the items in those domains. A mixed-effect model of repeated measures (MMRM) was used to estimate the change from baseline values.
Time frame: Baseline through Week 12
Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) Levels at Week 12
Time frame: Baseline, Week 12
Montelukast vs. Placebo: Change Fom Baseline in Morning Pre-bronchodilator Peak Expiratory Flow (PEF) at Week 12
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. The active comparator treatment arm of open-label montelukast was included in the study design so that the sensitivity of the study could be evaluated with respect to this secondary outcome measure of PEF. A mixed-effect model of repeated measures (MMRM) was used to estimate the absolute change from baseline values for the sensitivity comparison between montelukast (open-label, active comparator) and placebo study arms.
Time frame: Baseline through Week 12
Lebrikizumab vs. Placebo: Change From Baseline in Morning Pre-bronchodilator PEF at Week 12
Peak expiratory flow (PEF) is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. A mixed-effect model of repeated measures (MMRM) was used to estimate the absolute change from baseline values for the comparison between the double-blind lebrikizumab and placebo study arms.
Time frame: Baseline through Week 12
Lebrikizumab vs. Placebo: Number of Participants With Treatment Failure
Treatment failure was defined as a worsening of asthma symptoms (per investigator's assessment of participant report) in association with either relative decline in pre-bronchodilator FEV1 \>=20%; or \>=20% decline in morning pre-bronchodilator PEF on 2 consecutive days compared with baseline; or use of \>=10 puffs of albuterol metered dose inhaler (MDI); or \>=2 additional administrations (or any new use) of nebulized short-acting β-agonist (SABA) therapy within any calendar day; or need for any inhaled, oral, or parenteral corticosteroid or for a controller medication. The hazard ratio from the Cox Proportional Hazards model compared the risk of treatment failure for the lebrikizumab-treated and placebo participants.
Time frame: Baseline up to Week 12
Lebrikizumab vs. Placebo: Time to Treatment Failure
Treatment failure was defined as a worsening of asthma symptoms (per investigator's assessment of participant report) in association with either relative decline in pre-bronchodilator FEV1 \>=20%; or \>=20% decline in morning pre-bronchodilator PEF on 2 consecutive days compared with baseline; or use of \>=10 puffs of albuterol metered dose inhaler (MDI); or \>=2 additional administrations (or any new use) of nebulized short-acting β-agonist (SABA) therapy within any calendar day; or need for any inhaled, oral, or parenteral corticosteroid or for a controller medication. Time to treatment failure was estimated using Kaplan-Meier method.
Time frame: Basleine up to Week 12
Change From Baseline in Blood Eosinophil Count at Week 12
Time frame: Baseline, Week 12
Change From Baseline in Serum Periostin at Week 12
Time frame: Baseline, Week 12
Change From Baseline in Total Immunoglobulin E (IgE) Levels at Week 12
Time frame: Baseline, Week 12
Change From Baseline in C-C Motif Chemokine Ligand 13 (CCL-13) Levels at Week 12
Time frame: Baseline, Week 12
Change From Baseline in CCL-17 Levels at Week 12
Time frame: Baseline, Week 12
Maximum Serum Lebrikizumab Concentration (Cmax) After the First Dose
According to the protocol and statistical analysis plan, a single PK sample was collected per participant after the first dose at the expected time of the maximum serum lebrikizumab concentration.
Time frame: Predose on Day 0 and post-Day 1 dose on Day 7
Time to Reach Maximum Lebrikizumab Concentration After the First Dose (Tmax)
According to the protocol and statistical analysis plan, the Tmax, Week1 (first dose) value was estimated on the basis of a single pharmacokinetic (PK) timepoint per participant after the first dose, which was taken at the expected time of the maximum serum lebrikizumab concentration.
Time frame: Post-Day 1 dose on Day 7
Elimination Half-Life (t1/2) of Lebrikizumab
According to the protocol and statistical analysis plan, the t1/2 was estimated based on the seven total PK samples collected per participant.
Time frame: Predose on Days 0, 28, and 56, and on Days 7, 84, 112, and 140
Predose Serum Lebrikizumab Concentration (Cmin) at Week 4
Time frame: Predose on Day 28 (Week 4)
Serum Lebrikizumab Concentration at Week 12
Time frame: On Day 84 (Week 12)
| Milestone | Double-Blind: Lebrikizumab | Double-Blind: Placebo | Open-Label: Montelukast |
|---|---|---|---|
| Started | 105 | 106 | 102 |
| Received at least 1 dose of study drug | 104 | 105 | 101 |
| Completed | 98 | 98 | 91 |
| Not completed | 7 | 8 | 11 |
| Withdrew: Withdrawal by subject | 5 | 4 | 7 |
| Withdrew: Other | 1 | 1 | 0 |
| Withdrew: Adverse event | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 2 |
| Withdrew: Lack of efficacy | 0 | 1 | 1 |
Participants could only receive SABA therapy for asthma treatment as asthma reliever medication (\<10 puffs daily). SABA use was recorded in the eDiary. A mixed-effect model of repeated measures (MMRM) was used to estimate the absolute change from baseline values for the comparison between the double-blind lebrikizumab and placebo study arms.
| Puffs/day | Double-Blind: Lebrikizumab | Double-Blind: Placebo |
|---|---|---|
| Lebrikizumab vs. Placebo: Change From Baseline in Asthma Reliever Medication Use at Week 12 | -0.51 ± 0.108 | -0.55 ± 0.108 |
The AQLQ\[S\] was used to assess the participant's asthma-specific health-related quality of life. The 32-item questionnaire contains four domains: activity limitations, symptoms, emotional function, and environmental stimuli. The AQLQ\[S\] has a recall specification of 2 weeks. Participants were asked to think about how they had been during the previous 2 weeks and to respond to each of the 32 questions on a 7-point scale (7 = not impaired at all; 1 = severely impaired). An increase in the AQLQ score indicates a better quality of life. The overall AQLQ score is the mean of all 32 responses and the individual domain scores are the means of the items in those domains. A mixed-effect model of repeated measures (MMRM) was used to estimate the change from baseline values.
| Units on scale | Double-Blind: Lebrikizumab | Double-Blind: Placebo |
|---|---|---|
| Lebrikizumab vs. Placebo: Change From Baseline in the Standardized Asthma Quality of Life Questionnaire (AQLQ[S]) Overall Score at Week 12 | 0.62 ± 0.088 | 0.68 ± 0.086 |
| parts per billion (ppb) | Double-Blind: Lebrikizumab | Double-Blind: Placebo | Open-Label: Montelukast |
|---|---|---|---|
| Baseline (n= 104, 103, 103) | 52.85 ± 44.98 | 50.66 ± 44.49 | 65.89 ± 67.81 |
| Change at Week 12 (n= 84, 86, 92) | -31.85 ± 36.13 | -10.86 ± 28.41 | -13.21 ± 33.28 |
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. The active comparator treatment arm of open-label montelukast was included in the study design so that the sensitivity of the study could be evaluated with respect to this secondary outcome measure of PEF. A mixed-effect model of repeated measures (MMRM) was used to estimate the absolute change from baseline values for the sensitivity comparison between montelukast (open-label, active comparator) and placebo study arms.
| Liters/minute | Open-Label: Montelukast | Double-Blind: Placebo |
|---|---|---|
| Montelukast vs. Placebo: Change Fom Baseline in Morning Pre-bronchodilator Peak Expiratory Flow (PEF) at Week 12 | 5.92 ± 5.973 | 4.69 ± 5.872 |
Peak expiratory flow (PEF) is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. A mixed-effect model of repeated measures (MMRM) was used to estimate the absolute change from baseline values for the comparison between the double-blind lebrikizumab and placebo study arms.
| Liters/minute | Double-Blind: Lebrikizumab | Double-Blind: Placebo |
|---|---|---|
| Lebrikizumab vs. Placebo: Change From Baseline in Morning Pre-bronchodilator PEF at Week 12 | 1.63 ± 5.551 | 5.25 ± 5.565 |
Treatment failure was defined as a worsening of asthma symptoms (per investigator's assessment of participant report) in association with either relative decline in pre-bronchodilator FEV1 \>=20%; or \>=20% decline in morning pre-bronchodilator PEF on 2 consecutive days compared with baseline; or use of \>=10 puffs of albuterol metered dose inhaler (MDI); or \>=2 additional administrations (or any new use) of nebulized short-acting β-agonist (SABA) therapy within any calendar day; or need for any inhaled, oral, or parenteral corticosteroid or for a controller medication. The hazard ratio from the Cox Proportional Hazards model compared the risk of treatment failure for the lebrikizumab-treated and placebo participants.
| Participants | Double-Blind: Lebrikizumab | Double-Blind: Placebo |
|---|---|---|
| Lebrikizumab vs. Placebo: Number of Participants With Treatment Failure | 9 | 11 |
Treatment failure was defined as a worsening of asthma symptoms (per investigator's assessment of participant report) in association with either relative decline in pre-bronchodilator FEV1 \>=20%; or \>=20% decline in morning pre-bronchodilator PEF on 2 consecutive days compared with baseline; or use of \>=10 puffs of albuterol metered dose inhaler (MDI); or \>=2 additional administrations (or any new use) of nebulized short-acting β-agonist (SABA) therapy within any calendar day; or need for any inhaled, oral, or parenteral corticosteroid or for a controller medication. Time to treatment failure was estimated using Kaplan-Meier method.
| Days | Double-Blind: Lebrikizumab | Double-Blind: Placebo |
|---|---|---|
| Lebrikizumab vs. Placebo: Time to Treatment Failure | NA (NA to NA) | NA (NA to NA) |
| cells/microliter (cells/mcL) | Double-Blind: Lebrikizumab | Open-Label: Montelukast | Double-Blind: Placebo |
|---|---|---|---|
| Baseline (n= 104, 103, 103) | 230.10 ± 149.90 | 262.04 ± 169.84 | 233.30 ± 152.61 |
| Change at Week 12 (n= 84, 90, 91) | 55.12 ± 215.83 | -32.67 ± 165.94 | 33.52 ± 173.87 |
| Nanogram/milliliter (ng/mL) | Double-Blind: Lebrikizumab | Open-Label: Montelukast | Double-Blind: Placebo |
|---|---|---|---|
| Baseline (n= 104, 103, 103) | 53.85 ± 16.71 | 54.60 ± 16.18 | 55.37 ± 19.15 |
| Change at Week 12 (n= 88, 90, 91) | -3.92 ± 9.68 | -1.30 ± 7.72 | 0.33 ± 8.13 |
| Microgram (Mcg)/mL | Double-Blind: Lebrikizumab | Open-Label: Montelukast | Double-Blind: Placebo |
|---|---|---|---|
| Baseline (n= 103, 103, 102) | 994.46 ± 2032.99 | 565.42 ± 1051.63 | 868.28 ± 1422.97 |
| Change at Week 12 (n= 86, 89, 89) | -200.71 ± 643.46 | 26.10 ± 408.43 | -80.28 ± 582.12 |
| Picogram/mL (pg/mL) | Double-Blind: Lebrikizumab | Double-Blind: Placebo | Open-Label: Montelukast |
|---|---|---|---|
| Baseline (n= 104, 102, 103) | 192.79 ± 87.77 | 206.19 ± 91.04 | 201.34 ± 81.13 |
| Change at Week 12 (n= 88, 90, 90) | -35.79 ± 57.72 | 4.36 ± 72.00 | 0.19 ± 51.31 |
| pg/mL | Double-Blind: Lebrikizumab | Double-Blind: Placebo | Open-Label: Montelukast |
|---|---|---|---|
| Baseline (n= 104, 102, 103) | 506.49 ± 1476.14 | 365.48 ± 206.23 | 326.09 ± 189.33 |
| Change at Week 12 (n= 87, 90, 90) | -133.93 ± 764.14 | 23.93 ± 169.01 | 5.79 ± 134.93 |
According to the protocol and statistical analysis plan, a single PK sample was collected per participant after the first dose at the expected time of the maximum serum lebrikizumab concentration.
| Mcg/mL | Double-Blind: Lebrikizumab |
|---|---|
| Maximum Serum Lebrikizumab Concentration (Cmax) After the First Dose | 14.9 ± 5.91 |
According to the protocol and statistical analysis plan, the Tmax, Week1 (first dose) value was estimated on the basis of a single pharmacokinetic (PK) timepoint per participant after the first dose, which was taken at the expected time of the maximum serum lebrikizumab concentration.
| Days | Double-Blind: Lebrikizumab |
|---|---|
| Time to Reach Maximum Lebrikizumab Concentration After the First Dose (Tmax) | 7.04 ± 1.17 |
According to the protocol and statistical analysis plan, the t1/2 was estimated based on the seven total PK samples collected per participant.
| Days | Double-Blind: Lebrikizumab |
|---|---|
| Elimination Half-Life (t1/2) of Lebrikizumab | 23.7 ± 7.24 |
| Mcg/mL | Double-Blind: Lebrikizumab |
|---|---|
| Predose Serum Lebrikizumab Concentration (Cmin) at Week 4 | 9.58 ± 4.12 |
| Mcg/mL | Double-Blind: Lebrikizumab |
|---|---|
| Serum Lebrikizumab Concentration at Week 12 | 18.1 ± 6.46 |
FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. The active comparator treatment arm of open-label montelukast was included in the study design so that the sensitivity of the study could be evaluated with respect to the primary outcome measure, FEV1. Two mixed-effect models of repeated measures (MMRM) were used to estimate the absolute change from baseline values: one for the lebrikizumab vs. placebo primary comparison and the second for the montelukast vs. placebo sensitivity comparison.
| Liters | Double-Blind: Lebrikizumab | Double-Blind: Placebo | Open-Label: Montelukast |
|---|---|---|---|
| Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12 | 0.15 ± 0.033 | 0.07 ± 0.032 | 0.05 ± 0.032 |
Collected over Baseline up to Week 20. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lebrikizumab-Safety | 0/104 (0%) | 2/104 (1.9%) | 25/104 (24%) |
| Placebo-Safety | 0/103 (0%) | 1/103 (1%) | 24/103 (23.3%) |
| Montelukast-Safety | 0/103 (0%) | 0/103 (0%) | 33/103 (32%) |
| Event | Lebrikizumab-Safety | Placebo-Safety | Montelukast-Safety |
|---|---|---|---|
| Subdural haematomaInjury, poisoning and procedural complications | 0/104 | 1/103 | 0/103 |
| Cerebrospinal fluid leakageNervous system disorders | 0/104 | 1/103 | 0/103 |
| Anaphylactic reactionImmune system disorders | 1/104 | 0/103 | 0/103 |
| Malignant melanoma in situNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/104 | 0/103 | 0/103 |
| Event | Lebrikizumab-Safety | Placebo-Safety | Montelukast-Safety |
|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 6/104 | 12/103 | 12/103 |
| NasopharyngitisInfections and infestations | 9/104 | 5/103 | 11/103 |
| Upper respiratory tract infectionInfections and infestations | 9/104 | 5/103 | 8/103 |
| HeadacheNervous system disorders | 3/104 | 6/103 | 5/103 |
mITT Population: all participants who received at least one dose of study treatment, grouped according to the treatment assigned at randomization.
| Age, Continuous(years) | Double-Blind: Lebrikizumab | Double-Blind: Placebo | Open-Label: Montelukast | Total |
|---|---|---|---|---|
| Mean | 42.9 ± 13.8 | 44.7 ± 14.0 | 44.2 ± 13.3 | 43.9 ± 13.7 |
| Age, Customized(Participants) | Double-Blind: Lebrikizumab | Double-Blind: Placebo | Open-Label: Montelukast | Total |
|---|---|---|---|---|
| 18 to <30 years | 22 | 19 | 17 | 58 |
| 30 to <50 years | 47 | 44 | 48 | 139 |
| 50 to <65 years | 28 | 33 | 32 | 93 |
| ≥65 years | 7 | 9 | 4 | 20 |
| Sex: Female, Male(Participants) | Double-Blind: Lebrikizumab | Double-Blind: Placebo | Open-Label: Montelukast | Total |
|---|---|---|---|---|
| Female | 63 | 66 | 61 | 190 |
| Male | 41 | 39 | 40 | 120 |
| Ethnicity (NIH/OMB)(Participants) | Double-Blind: Lebrikizumab | Double-Blind: Placebo | Open-Label: Montelukast | Total |
|---|---|---|---|---|
| Hispanic or Latino | 10 | 11 | 10 | 31 |
| Not Hispanic or Latino | 93 | 94 | 91 | 278 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Double-Blind: Lebrikizumab | Double-Blind: Placebo | Open-Label: Montelukast | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 | 2 |
| Asian | 2 | 4 | 5 | 11 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 13 | 20 | 10 | 43 |
| White | 88 | 81 | 84 | 253 |
| More than one race | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Biomarker Classification According to Periostin and Eosinophil Levels(Participants) | Double-Blind: Lebrikizumab | Double-Blind: Placebo | Open-Label: Montelukast | Total |
|---|---|---|---|---|
| Periostin ≥50 ng/ml and Eosinophils ≥300 cells/ul | 21 | 23 | 21 | 65 |
| Periostin ≥50 ng/ml and Eosinophils <300 cells/ul | 37 | 41 | 34 | 112 |
| Periostin <50 ng/ml and Eosinophils ≥300 cells/ul | 9 | 11 | 6 | 26 |
| Periostin <50 ng/ml and Eosinophils <300 cells/ul | 37 | 30 | 40 | 107 |
| Pre-bronchodilator FEV1(Liters (L)) | Double-Blind: Lebrikizumab | Double-Blind: Placebo | Open-Label: Montelukast | Total |
|---|---|---|---|---|
| Mean | 2.39 ± 0.59 | 2.31 ± 0.63 | 2.38 ± 0.57 | 2.36 ± 0.60 |
Ran from Jun 2014 to primary completion in Jan 2016, 19 months.
Results were first posted in Jul 2026, 10 years 5 months after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 19 months is below that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lebrikizumab